Suwanwattana, P.; Han, M.; Nopsopon, T.; Phutrakool, P.; Samuthpongtorn, C.; Pongpirul, W.; Prasithsirikul, W.; Pongpirul, K. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 NCoV-19 Vaccine. Microbiology Research 2023, 14, 810–818, doi:10.3390/microbiolres14020057.
Suwanwattana, P.; Han, M.; Nopsopon, T.; Phutrakool, P.; Samuthpongtorn, C.; Pongpirul, W.; Prasithsirikul, W.; Pongpirul, K. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 NCoV-19 Vaccine. Microbiology Research 2023, 14, 810–818, doi:10.3390/microbiolres14020057.
Suwanwattana, P.; Han, M.; Nopsopon, T.; Phutrakool, P.; Samuthpongtorn, C.; Pongpirul, W.; Prasithsirikul, W.; Pongpirul, K. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 NCoV-19 Vaccine. Microbiology Research 2023, 14, 810–818, doi:10.3390/microbiolres14020057.
Suwanwattana, P.; Han, M.; Nopsopon, T.; Phutrakool, P.; Samuthpongtorn, C.; Pongpirul, W.; Prasithsirikul, W.; Pongpirul, K. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 NCoV-19 Vaccine. Microbiology Research 2023, 14, 810–818, doi:10.3390/microbiolres14020057.
Abstract
Vaccines are crucial for controlling the COVID-19 pandemic, and booster doses are becoming increasingly important. This study aimed to assess the efficacy of the ChAdOx1 nCoV-19 vaccine from AstraZeneca as a third dose in healthcare workers at different time intervals (one, three, and six months). Two methods to measure immune response—ELISA (EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany) and ELISpot (Mabtech AB, Macka Strand, Sweden)—were used. A total of 170 participants were included in the study. The results showed that while IgG levels decreased at six months compared to levels at one and three months, they were still significantly higher than the baseline. Furthermore, neutralizing levels at three and six months after the third dose were not significantly different. These findings suggest that the immune response induced by the vaccine is robust and effective for several months. These results have significant implications for public health policymakers, as they provide strong support for booster vaccinations. The ChAdOx1 nCoV-19 vaccine appears to be a reliable option for preventing the spread of COVID-19, and this study provides valuable information for healthcare workers and policymakers in managing the pandemic.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.